Introduction and Opening Remarks James A. Zwiebel by getanewcar


									      AACR Science Policy Forum:
Cancer Drug Development as a Successful
  Public-Private Enterprise – The NCI in
        Partnership with Industry
                         April 20, 2009

Miguel A. Villalona, MD                    James Zwiebel, MD
Professor of Internal Medicine     Chief, Investigational Drug Branch
 & Pharmacology                   Cancer Therapy Evaluation Program
Division of Hematology & Oncology
Ohio State University                              NCI
Division of Cancer Treatment and Diagnosis
Forum Agenda
•   The NCI Developmental Therapeutics Program: From molecules to
           Jerry M. Collins, DTP, DCTD, NCI, Rockville, MD
•   The NCI Cancer Imaging Program: Developing imaging tools for
    drug development
           Paula Jacobs, CIP, DCTD, NCI, Bethesda, MD
•   The NCI Experimental Therapy Program: Biomarker assay validation
    and Phase 0 trials
           Joseph E. Tomaszewski, DCTD, NCI, Bethesda, MD
•   The NCI Cancer Therapy Evaluation Program: Therapeutics in the
    public interest
           Jeffrey Abrams, CTEP, DCTD, Rockville, MD
•   Collaborative drug development with the NCI: An industry
           David P. Schenkein, Genentech, Inc., South San Francisco, CA
•   Panel Discussion: All speakers plus Merrill Egorin, M.D., University
    of Pittsburgh

To top